ClinicalTrials.gg
Enrolling by invitationNCT06084533Updated Apr 2, 2026

CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

An observational study in Parkinson Disease, sponsored by Washington University School of Medicine. Enrolling by invitation at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Washington University School of Medicine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
80
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Parkinson Disease by Washington University School of Medicine — 7 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Washington University School of Medicine.

Planned enrollment
10th of 13
80 · median 174
Started
2024
with 1 other
Observational
13 of 32
6 open now
Registered
29th of 32
by date

Among the 32 studies in Parkinson Disease by Washington University School of Medicine, this one is the 10th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2024, is one of 13 observational ones, and was the 29th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 32 studies in Parkinson Disease by Washington University School of Medicine are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Parkinson Disease by Washington University School of Medicine, or all of them as a file.
02

Study summary

Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called [11C]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with [11C]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A total of 50 participants with idiopathic PD and up to 30 healthy control participants are to be studied. Some of these participants will be recruited from existing research studies. Others will be recruited from the clinic, the community, and a registry of healthy volunteers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
  • Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.

Exclusion criteria

Exclusion Criteria:

  • any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
  • history of brain surgery or major head trauma
  • major medical/systemic illness
  • severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
  • major drug abuse
  • history of long term use of anti-dopaminergic medication
  • chronic treatment with immunomodulatory or anti-inflammatory medications
  • weight over 300 lbs
  • to or inability to tolerate MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Parkinson Disease

    Drug: [11C]-CS1P1

  • Healthy Control

    Drug: [11C]-CS1P1

Interventions

  • Drug[11C]-CS1P1

    Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.

06

What researchers measure

Primary outcomes

  1. PET imaging studies of [11C]-CS1P1 in healthy control participants and participants with Parkinson Disease.

    The investigators hypothesize that specific binding of \[11C\]-CS1P1 is elevated in participants with neurodegenerative disease of the central nervous system compared to healthy control participants.

    Time frame: At the time of PET scan

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Feb 2029, 60 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 60 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Oct 16, 2023
StartActual
Jan 10, 2024
Primary completionEst.
Feb 1, 2029
CompletionEst.
Feb 28, 2029
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06084533
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Jan 10, 2024
Primary completion
Feb 1, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Apr 2, 2026

Study contacts

Robert L White, MD, PhD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion